• Liquidia Corporation has been added to the S&P SmallCap 600 Index and earlier this week presented four posters at the PHA 2026 International PH Conference in Dallas, including new data from the ASCENT study of its YUTREPIA inhalation powder in pulmonary hypertension associated with interstitial lung disease.
• Beyond the index inclusion, the fresh ASCENT and caregiver data highlight how Liquidia is working to shape both clinical practice and broader pulmonary hypertension care models.
• Next, we’ll examine how Liquidia’s inclusion in the S&P SmallCap 600 could influence its existing investment narrative built around YUTREPIA.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Liquidia Investment Narrative Recap

To own Liquidia, you need to believe YUTREPIA can sustain meaningful prescription growth and evolve into a durable pulmonary hypertension franchise, while L606 adds longer term diversification. The S&P SmallCap 600 inclusion may broaden the shareholder base and liquidity, but it does not materially change the near term focus on YUTREPIA execution or key risks around payer economics, manufacturing scale up and how future data may influence physician preferences.

Among recent updates, the new ASCENT data presented at PHA 2026 looks most relevant, because it directly informs how clinicians view YUTREPIA in PH ILD, including patient reported cough outcomes and treatment durability over 24 weeks. Those real world observations help shape expectations for persistence on therapy, which ties back to the core revenue and margin catalysts investors are watching as Liquidia ramps capacity and works to deepen prostacyclin use across its target prescriber base.

Yet while index inclusion and encouraging ASCENT findings support the story, investors should be aware of how sensitive Liquidia still is to long term shifts in pulmonary hypertension treatment patterns and competing delivery technologies...

Liquidia's narrative projects $717.7 million revenue and $299.9 million earnings by 2029. This requires 118.1% yearly revenue growth and a $424.0 million earnings increase from $-124.1 million today.

Uncover how Liquidia's forecasts yield a $44.00 fair value, a 39% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenue could climb to about US$555.6 million and earnings to roughly US$23.4 million by 2028, yet they still saw meaningful downside risk if YUTREPIA uptake slows after an early surge and dependence on a single drug franchise remains high, so it is worth comparing those more cautious views with how the new index inclusion and ASCENT results might eventually reshape expectations.

Explore 5 other fair value estimates on Liquidia - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Liquidia research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.